510(k) · Cleared
ClearedT-Rex Biopsy Forceps
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Boston Scientific Corp · DWZ Device, Biopsy, Endomyocardial
Cleared on Dec 16, 1997 as substantially equivalent to K870186 (Mansfield Scientific, Inc., 1987) after a 70-day review. Its family tree reaches back 1 generation to 1987. 2 later devices descend from it.
- Decided
- Dec 16, 1997
- Review
- 70 days
- Class
- Class II
- Product code
- DWZ
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to K870186 (1987). 2 later devices descend from it, 1 citing it directly.
- Root · 1 generation backK870186 Endomyocardial Biopsy DeviceMansfield Scientific, Inc. · 1987
- This deviceK973818 T-Rex Biopsy ForcepsBoston Scientific Corp · 1997
- Descendant · cites it directly · 1 of its ownK170726 Biopsy ForcepsFehling Instruments GmbH & Co. KG · 2017
- Descendant · 2 generations on · 0 of its ownK252722 Biopsy ForcepsFehling Instruments GmbH · 2025
Most influential descendants
Showing 2 of 2 · See allView FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | K870186 | Endomyocardial Biopsy Device | Mansfield Scientific, Inc. | 1987 | — |
| 0 (this device) | K973818 | T-Rex Biopsy Forceps | Boston Scientific Corp | 1997 | — |
| +1 | K170726 | Biopsy Forceps | Fehling Instruments GmbH & Co. KG | 2017 | — |
| +2 | K252722 | Biopsy Forceps | Fehling Instruments GmbH | 2025 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2017 | 1 | 0 |
| 2025 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in DWZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new DWZ device
- #1 K252722 Biopsy Forcepsscore 10.7 · 3 generations · no Class I recall
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K870186 | Endomyocardial Biopsy DeviceSummary page 2…remain the same, as well as the basic structure and operation of the device. The following table summarizes the modifications. jaws/housing Component Bycep® Forceps (K870186) T-REX Forceps End-Effector and Jaw Assembly Jaws Machined to sharpness Proprietary sharpening method Actuator links Soft or se… | 1987 |
What descends from it? (2)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K170726 | Biopsy Forceps | 2017 | 1 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Its one ancestor has no recall.
- Of its descendants, K170726 (Fehling Instruments GmbH & Co. KG, 2017) has gone furthest, with 1 descendant of its own.
How does its category compare?
All DWZ devicesDWZ Device, Biopsy, Endomyocardial: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · DWZ
1in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · DWZ
Too few DWZ 510(k)s in any year since 2007 to give a median.
Recalls per year · DWZ
No recall names DWZ since 2007.
Adverse event reports per year · DWZ
1in 2025
MAUDE reports naming product code DWZ, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 1 | — | 0 | 2 |
| 2008 | 0 | — | 0 | 1 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 3 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 1 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 1 |
| 2016 | 0 | — | 0 | 1 |
| 2017 | 1 | — | 0 | 4 |
| 2018 | 0 | — | 0 | 7 |
| 2019 | 0 | — | 0 | 5 |
| 2020 | 0 | — | 0 | 5 |
| 2021 | 0 | — | 0 | 5 |
| 2022 | 0 | — | 0 | 14 |
| 2023 | 0 | — | 0 | 10 |
| 2024 | 0 | — | 0 | 4 |
| 2025 | 1 | — | 0 | 1 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The T*REX™ biopsy forceps are intended to obtain endomyocardial biopsy specimens. The specimens are taken for diagnosis of diseased heart tissue or for identification and monitoring of rejection factors in a transplanted heart.
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K973818 · printed Nov 5, 2026
Cite this page
510(k) Report. “K973818: T-Rex Biopsy Forceps.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K973818
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026